LRRK2 and Parkinson disease: Third, our phenoconversion rates to PD in LRRK2 G2019S carriers, although 10-fold higher than non-carriers, indicate large sample sizes would still be needed to adequately power clinical trials.11 This suggests that phenoconversion is unlikely to be a good primary outcome measure until we find a way to enrich the candidate section.